Browsing Tag
Hyperimmune
1 post
IV Hyperimmune Immunoglobulin No Help in Severe COVID
Hyperimmune intravenous immunoglobulin (hIVIG) added to standard of care, including remdesivir (Veklury), did not improve clinical outcomes among hospitalized patients with severe COVID-19, a randomized trial found. People given hIVIG had no better chance of a better clinical outcome at day 7 compared with those assigned placebo (adjusted OR 1.06, 95% CI 0.77-1.45), reported Mark…